Loading the section
Prices delayed by 15 minutes
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Iovance Biotherapeutics, Inc. trades on Nasdaq under the ticker IOVA. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks IOVA has traded between 1.76 $ and 15.30 $. As of 09 October 2026 the price stood 85.30 % of the way from the 52-week low to the high.
Over one year IOVA shares rose 510.55 %; over six months they rose 231.92 %. Volatility over 90 days is 109.33 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 20.4, above the sector median of 3.9. Price to book is 8.1, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 12.65 | 13.40 | 12.62 | 13.31 | 15M |
| 07 October 2026 | 12.52 | 13.15 | 12.31 | 12.92 | 15M |
| 06 October 2026 | 14.21 | 14.21 | 12.92 | 12.96 | 19M |
| 05 October 2026 | 14.03 | 14.41 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Iovance Biotherapeutics, Inc. (IOVA) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2025-12-31, revenue was 263.5m $, net income was -391.0m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:825 INDUSTRIAL ROAD 4TH FLOOR, SAN CARLOS, CA, 94070, US
Iovance Biotherapeutics, Inc. reported revenue of 286M $ and a net loss of 354M $ over the last four quarters. Net margin is −123.90 %. Revenue changed by +34.29 % year over year. Earnings per share are −0.92 $. Market capitalisation is 5.8B $.
IOVA has a return on equity of −49.03 %, below the sector median of −41.68 %. Return on assets is −38.23 %, below the sector median of −32.11 %. Operating margin is −127.16 %, below the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 111.70 | +1.69 % | 251M |
| BIIBBiogen Inc. | 226.01 | +3.47 % | 224M |
| TECHBio-Techne Corp | 72.46 | +0.01 % | 215M |
| 13.71 |
| 14.15 |
| 12M |
| 02 October 2026 | 14.45 | 14.75 | 13.95 | 14.22 | 12M |
| 01 October 2026 | 14.76 | 15.03 | 14.19 | 14.23 | 16M |
| 30 September 2026 | 14.65 | 15.11 | 14.10 | 14.82 | 29M |
| 29 September 2026 | 12.79 | 15.30 | 12.78 | 14.45 | 78M |
| 28 September 2026 | 10.88 | 11.17 | 10.68 | 10.99 | 12M |
| 25 September 2026 | 10.90 | 11.13 | 10.69 | 11.00 | 13M |
| 24 September 2026 | 10.40 | 10.83 | 10.15 | 10.80 | 12M |
| 23 September 2026 | 10.69 | 10.85 | 10.12 | 10.19 | 16M |
| 22 September 2026 | 10.18 | 10.80 | 10.03 | 10.64 | 16M |
| 21 September 2026 | 10.43 | 10.64 | 10.03 | 10.19 | 13M |
| 18 September 2026 | 10.12 | 10.27 | 9.83 | 10.25 | 23M |
| 17 September 2026 | 10.25 | 10.98 | 9.99 | 10.02 | 24M |
| 16 September 2026 | 9.45 | 9.93 | 9.44 | 9.87 | 20M |
| 15 September 2026 | 9.21 | 9.38 | 8.98 | 9.36 | 11M |
| 14 September 2026 | 8.56 | 9.41 | 8.54 | 9.26 | 21M |
| 11 September 2026 | 8.25 | 8.70 | 8.08 | 8.60 | 12M |